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A Quantitative Increase in Regulatory T Cells Controls
Development of Vitiligo
Shilpak Chatterjee1, Jonathan M. Eby2, Amir A. Al-Khami1, Myroslawa Soloshchenko1, Hee-Kap Kang2,
Navtej Kaur1, Osama S. Naga1, Anuradha Murali1, Michael I. Nishimura3, I. Caroline Le Poole2 and
Shikhar Mehrotra1
T-cell cytolytic activity targeting epidermal melanocytes is shown to cause progressive depigmentation and
autoimmune vitiligo. By using the recently developed transgenic mice h3TA2 that carry T cells with a HLA-A2-
restricted human tyrosinase peptide (h-Tyr)–reactive TCR and develop spontaneous vitiligo from an early age, we
addressed the mechanism regulating autoimmune vitiligo. Depigmentation was significantly impaired only in
IFN-g-knockout h3TA2 mice but not in TNF-a- or perforin-knockout h3TA2 mouse strains, confirming a central
role for IFN-g in vitiligo development. In addition, regulatory T cells (Tregs) were relatively abundant in h3TA2-
IFN-g / mice, and depletion of the Treg–engaging anti-CD25 antibody fully restored the depigmentation
phenotype in h3TA2-IFN-g / mice, mediated in part through the upregulation of proinflammatory cytokines
such as IL-17 and IL-22. Further therapeutic potential of Treg abundance in preventing progressive depigmenta-
tion was evaluated by adoptively transferring purified Treg or using rapamycin. Both the adoptive transfer of Tregs
and the use of rapamycin induced a lasting remission of vitiligo in mice treated at the onset of disease, or in mice
with established disease. This leads us to conclude that reduced regulatory responses are pivotal to the
development of vitiligo in disease-prone mice, and that a quantitative increase in the Treg population may be
therapeutic for vitiligo patients with active disease.
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INTRODUCTION
Vitiligo is a depigmenting disorder of the skin characterized by
the appearance of white macules due to a selective and
progressive loss of melanocytes from the epidermis (Le Poole
et al., 1993, 1996). The etiology of vitiligo remains to be
elucidated, but autoimmune factors have strongly been
implicated in disease pathogenesis (Ongenae et al., 2003;
Lambe et al., 2006). Histopathological studies reveal that
vitiligo skin is populated with inflammatory lymphocytic
infiltrates consisting of both activated CD4þ and CD8þ T
cells (Steitz et al., 2004; van den Boorn et al., 2009). In
addition, the association of vitiligo with immunotherapy of
melanoma using activated cytotoxic T cells specific for shared
tumor antigens and melanosomal proteins further supports the
autoimmune etiology of vitiligo (Sakai et al., 1997; Yee et al.,
2000; Mehrotra et al., 2012).
Extensive studies have addressed the role of immune
effector molecules in melanocyte destruction in vitiligo
(Oyarbide-Valencia et al., 2006; Sandoval-Cruz et al., 2011).
T cells present in the perilesional area of vitiligo skin are often
polarized toward type 1 effector function and produce
elevated levels of inflammatory cytokines IFN-g, IL-17, and
TNF-a (Mashiah and Brenner, 2008; van den Boorn et al.,
2009; Wang et al., 2011). Studies with a recently developed
mouse model of vitiligo suggest a multifaceted role for IFN-g
in the onset of vitiligo and predict that IFN-g might regulate
the accumulation of inflammatory self-reactive T cells to
perilesional areas by upregulating the expression of chemo-
kine receptors on T cells (Gregg et al., 2010). However,
failure to completely resolve the disease development in
chemokine receptor–deficient mice (Gregg et al., 2010)
suggests the involvement of additional mechanisms in
vitiligo development.
The development of autoimmunity reflects inefficient per-
ipheral tolerance of the host immune system. Regulatory T
cells (Tregs) characterized by the expression of forkhead box
P3 (FoxP3) signature transcription factor have a pivotal role in
maintaining peripheral tolerance, and in restraining autoreac-
tive T cells from mediating autoimmune responses (Baecher-
Allan and Hafler, 2006; Brusko et al., 2008). Paucity or
functional defects in the Treg population have been
described in various autoimmune disorders (Cvetanovich
and Hafler, 2010). Our studies involving skin biopsies from
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patients with vitiligo showed a reduced abundance of Tregs in
the skin of vitiligo patients with no significant difference in
their peripheral abundance or functionality (Klarquist et al.,
2010). A decrease in the percentage of Treg recruitment to
skin from the peripheral blood is also documented (Ben
Ahmed et al., 2012). Thus, it is increasingly clear that Tregs
do influence the development of vitiligo. Herein we tested
whether Tregs have any role in the development of vitiligo in a
recently developed mouse model h3TA2 (human TIL–derived
Tyrosinase TCR transgenic on HLA-A2) that develops sponta-
neous vitiligo progressive with age (Mehrotra et al., 2012).
These h3TA2 mice display prominent and progressive, T-cell-
mediated depigmentation of the pelage during adolescence,
similar to human vitiligo. To quantitatively increase the Tregs
in the vitiligo-prone h3TA2 mice, we either adoptively
transferred Tregs from a genetically matched mouse or
treated mice with the Treg inducer rapamycin (Daniel et al.,
2010; Scotta et al., 2013). Our data show a potential for using
such strategies aimed at exploiting Tregs in controlling
autoimmune depigmentation.
RESULTS
IFN-c is required for development of vitiligo
Transgenic h3TA2 mice with h-Tyr–reactive high–affinity TCR
on a HLA-A2 background rapidly develop spontaneous
vitiligo, as is evident by the appearance of depigmenting ears
and tail that continuously progresses with age (Mehrotra et al.,
2012). Littermate HLA-A2þTCR mice do not exhibit any
depigmentation implicating the crucial involvement of the
transgenic T cells in autoimmune vitiligo (Figure 1a). To gain
insight into the involvement of T-cell effector molecules in
the development of vitiligo, we generated vitiligo-prone
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Figure 1. Development of vitiligo in h3TA2 mice depends on IFN-c. (a) Degree of spontaneous depigmentation is shown in three representative age-matched
h3TA2 (8 weeks) and wild-type (HLA-A2) mice. Upper panel shows dorsal scans, whereas the lower panel shows ventral scans of respective mice. (b) A
comparative picture showing the development of vitiligo in 8-week-old h3TA2-IFN-g / , h3TA2-TNF-a / , or h3TA2-perforin / mice. (c) Percentage of
depigmentation was calculated from five HLA-A2, h3TA2, h3TA2-IFN-g / , h3TA2-TNF-a / , and h3TA2-perforin / mice. *Po0.05. Results are shown as a
mean of percent depigmentation±SD. (d) Splenocytes (n¼ 4) from either 8-week-old h3TA2 or h3TA2-IFN-g / , h3TA2-TNF-a / , and h3TA2-perforin /
mice were stained using TCR-specific human Vb12 antibody to determine the abundance of transgenic T cells and (e) fluorochrome-conjugated CD44 and CD62L.
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h3TA2 mice on either an IFN-g, TNF-a, or perforin-knockout
background. Transgenic h3TA2 mice developed 6.9±3.65%
depigmentation of the dorsal pelage. Importantly, the absence
of IFN-g led to the complete control of the disease in h3TA2
mice (at 2.5±2.09% depigmentation—similar to wild-type
control animals at that age; Figure 1b and c). The h3TA2-IFN-
g / mice were free from any sign of vitiligo even after
21 weeks of observation. However, genetic ablation of TNF-a
(depigmentation 7.4±1.36%) or perforin (depigmentation
6.9±3.39%) had no effect on the development of vitiligo,
and the progression of depigmentation was kinetically
indistinguishable from the wild-type h3TA2 mice evaluated
at 8 weeks of age (Figure 1b and c).
Further, we tested whether the protective effect of IFN-g
deficiency on vitiligo development was either due to the
insufficient number or impaired activation of transgenic T cells
present in h3TA2-IFN-g / mice. Results in Figure 1d
show that the percentage of transgenic T cells present
among splenocytes of either h3TA2-IFN-g / (49.3±2.7%),
h3TA2-TNF-a / (47.9±3.0%), or h3TA2-perforin /
(48.1±1.7%) are comparable to wild-type h3TA2 (51.2±
1.3). As the TCR transgenic T cells were quantitatively the
same, we evaluated whether they were qualitatively different.
When comparing splenocyte phenotype to define effector,
central memory, or effector memory phenotype among h3TA2
animals (n¼6), we did not observe any significant difference
in the phenotype of the transgenic T cells with regard to central
memory markers (CD62LhiCD44hi) in h3TA2-IFN-g / mice
as compared with h3TA2, h3TA2-TNF-a / , or h3TA2-
perforin / mice (Figure 1e). The lower panel with histogram
shows that the mean percentage of transgenic T cells coex-
pressing CD62L and CD44 is similar from four different mice
evaluated. These observations indicate that IFN-g may have an
important role in vitiligo development. As systemic numbers
of effector T cells (Teffs) are unchanged in IFN-g-knockout
mice, depigmentation could be due to reduced trafficking of
T cells to target sites in the skin.
Skin homing by Teffs
To gain insights into the chemokine receptors responsible for
skin infiltration by Teffs, we generated h3TA2 mice carrying a
knockout mutation for either CXCR3 or CCR5, two key
chemokines that have been shown to be responsible for T-cell
infiltration to the skin (Akashi et al., 2005; Mohan et al., 2005;
Mora and von Andrian, 2006). However, the rates of
depigmentation in h3TA2-CXCR3 / and h3TA2-CCR5 /
mice were similar to that of h3TA2 mice, suggesting that T-cell
migration in high–affinity tyrosinase TCR–bearing h3TA2 mice
is independent of chemokine receptor CXCR3 or CCR5
expression by transgenic T cells (Figure 2a). Our data suggest
that rather than the T-cell infiltration, it is the absence of IFN-g
in h3TA2 mice that controls the development of vitiligo. The
level of effector cytokine IFN-g–producing tyrosinase–reactive
T cells upon stimulation with the cognate epitope was similar
in all strains of h3TA2 mice (Figure 2b). Next, we tested
whether IL-17, a cytokine also implicated in the pathogenesis
of vitiligo (Bassiouny and Shaker, 2011), is responsible for
depigmentation in h3TA2 mice. Our data in Figure 2c show
that splenic and peripheral blood T cells in h3TA2 mice
primarily secreted IFN-g and no IL-17 upon stimulation with
peptide or phorbol 12-myristate 13-acetate/ionomycin. As
IFN-g could also affect the Treg function (Caretto et al.,
2010), we further examined the role of Treg cells in h3TA2
strains.
Effector versus Treg ratio affects the development of vitiligo in
h3TA2 mice
Functional impairment or paucity of the Treg subset may
disrupt the delicate balance with Teffs leading to the devel-
opment of autoimmunity. Notably, Treg versus Teff ratio has
been shown to determine the induction of protective immune
responses and also curtail the tissue damage by inflammatory
processes. Thus, we tested whether there is functional rele-
vance to Treg in the development of vitiligo in h3TA2 mice.
As IFN-g deficiency protects h3TA2 mice from developing
vitiligo, we examined whether any qualitative or quantitative
differences exist in the Treg compartment of the spleen and
blood between IFN-g-competent and -knockout h3TA2 mice.
We found that Treg (CD4þCD25þFoxP3þ ) cells obtained
from all h3TA2 strains (i.e., h3TA2-perforin / , h3TA2-
TNFa / , h3TA2-IFN-g / , h3TA2-CXCR3 / , and h3TA2-
CCR5 / ) are functionally suppressive (Supplementary Figure
S1a online), whereas a numerically significant increase in Treg
cells was found in h3TA2-IFN-g / mice compared with
h3TA2 (Figure 3a and b and Supplementary Figure S1b
online). Interestingly, a comparison of the Treg numbers
between C57BL/6 and IFN-g / mice showed no significant
difference (Supplementary Figure S1b online). Next, we
wanted to determine whether the aforementioned increase
in regulatory T cells significantly alters the Teff versus Treg
ratio in h3TA2-IFN-g / mice. As shown in Figure 3c, the
Teff to Treg ratio was markedly decreased in h3TA2-IFN-g /
mice as compared with wild-type h3TA2 mice.
As an increased abundance of Treg abrogates the develop-
ment of vitiligo in h3TA2-IFN-g / mice, we next tested
whether the depletion of Treg in h3TA2-IFN-g / mice
renders them prone to vitiligo. Treatment of h3TA2-IFN-g /
mice (n¼3) with anti-CD25 antibody for 12 weeks depleted
Treg (Figure 3d), and markedly accelerated the development
of vitiligo in h3TA2-IFN-g / mice, whereas no depigmenta-
tion was observed in untreated age-matched h3TA2-INF-g /
control mice (Figure 3e). As IFN-g was not present in these
knockout mice that developed vitiligo after the depletion of
Tregs, we examined whether vitiligo development was
mediated by other cytokines. As a role of IL-17 in the
development of vitiligo has been implied, we tested TCR-
restimulated splenocytes from all groups of experimental mice
for IL-17 and IL-22 secretion. Our data show that transgenic
T cells obtained from the h3TA2-IFN-g / mice markedly
increased secretion of both cytokines after Treg depletion
(Figure 3f). Immunostaining also showed an increase in CD3þ
IL-17þ cells infiltrating the skin from h3TA2-IFN-g / mice
treated with anti-CD25 (Figure 3g). Intrigued by these data, we
further evaluated multiple cytokines/chemokines in a multi-
plex protein assay. Our data show that upon specific stimula-
tion with tyrosinase peptide, an array of proinflammatory
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cytokines were secreted specifically by transgenic T cells
obtained from h3TA2-IFN-g / mice that were depleted of
Treg (Figure 3h). Thus, it appears that although the status of
IFN-g may not solely define the disease, a quantitative
modulation of Treg can have a role in the development of
vitiligo by promoting the expansion of other proinflammatory
cytokine secretion by transgenic T cells. These findings
indicated a central role of Treg in the development of vitiligo
and led us to test whether a quantitative increase of Treg
inhibits Teff function and prevents vitiligo progression.
Transfer of Treg effectively halts the progression of vitiligo in
h3TA2 mice
As the presence of an increased number of Tregs affects the
Teff versus Treg ratio and protects h3TA2-IFN-g / mice from
the development of vitiligo, we tested whether enhancing the
Treg compartment could halt the depigmentation process in
h3TA2 mice. We sorted Treg from FoxP3-EGFP-A2 mice
based on the expression of CD4þCD25þGFPþ (Figure 4a)
and transferred them to h3TA2 mice. A group of five mice
were adoptively transferred with 2 105 Tregs at 3 weeks of
age and were followed for 6 weeks. We found that the transfer
of Treg almost completely subverts the progression of vitiligo
in h3TA2 mice. The effect was sustained for the length of a
6-week observation period, during which untreated animals
were 19.7±3.17% depigmented versus 2.9±2.72% in the
treated group (Figure 4b). Flow cytometric analysis after 6
weeks of Treg transfer revealed that both the percentage and
the total number of CD4þCD25þFoxP3þcells were signifi-
cantly higher (Po0.01) in h3TA2 mice as compared with
untreated mice (Figure 4c). Although a quantitative increase in
Treg halted vitiligo progression, we did not observe any
repigmentation of areas that were already devoid of pigment.
Notably, the number of antigen-specific T cells in Treg-treated
mice remained unchanged as compared with untreated
animals (Figure 4d). Thus, the presence of transferred Treg
helped to maintain a lower Teff versus Treg ratio in the treated
group over time (Figure 4e) and may be responsible for
controlling depigmentation.
Adoptively transferred Treg do not affect the functionality of
h3TA2 transgenic T cells
To evaluate whether the long-term persistence of transferred
Treg in h3TA2 mice affects the functionality of melanocyte-
reactive T cells, we stimulated unfractionated splenocytes
from treated or untreated h3TA2 mice with a cognate peptide
and analyzed them for intracellular secretion of various
cytokines by flow cytometry. Results in Figure 5a show that
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Figure 2. Development of vitiligo in h3TA2 mice is independent of CCR5 or CXCR3. (a) Comparative pictures for the development of vitiligo among age-matched
(8 weeks) h3TA2, h3TA2-CXCR3 / , or h3TA2-CCR5 / mice. Lower panel shows the quantification for percent depigmentation between the groups on top.
Results are shown as a mean of percent depigmentation±SD. (b) Transgenic T cells (2105) from various h3TA2 strains were TCR stimulated overnight with
cognate epitope (human tyrosinase peptide (h-Tyr)) and control epitope (MART-1). Supernatant was then evaluated for IFN-g secretion using ELISA. (c) Splenic or
peripheral blood transgenic T cells (2 105) from h3TA2 mice were stimulated either with TCR or with phorbol 12-myristate 13-acetate (PMA)/ionomycin
(500 ng ml1) and stained for intracellular cytokine IFN-g and IL-17.
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transgenic T cells from both Treg-transferred and -untreated
groups were functionally comparable in their ability to secrete
effector cytokines upon stimulation with cognate antigen. The
absence of any marked suppression of peripheral Teffs despite
the increase in Treg numbers after an adoptive transfer raises
the possibility that the observed decrease in vitiligo could be
due to an increased infiltration of Tregs in the skin that results
in localized suppression of Teffs. We thus assessed skin
infiltration of Treg by FoxP3/CD3 staining of treated versus
untreated h3TA2 mice. As shown in Figure 5b, Tregs were
indeed more abundant in treated skin. These findings led
us to believe that restoring Treg responses in the skin can
curtail depigmentation, and that drug-induced Treg
stimulation (as by mammalian target of rapamycin inhibitor)
has the potential to serve as a treatment for patients with active
disease.
Rapamycin treatment can control vitiligo in h3TA2 mice
Rapamycin has been used in vitro for the expansion of CD4þ
CD25þFoxp3þ Tregs and also preserves the suppressive
effects of Tregs in vivo (Daniel et al., 2010; Scotta et al.,
2013). These observations prompted us to explore the thera-
peutic potential of rapamycin to control vitiligo in h3TA2
mice. Mice at 3 weeks of age were treated with rapamycin at
5 mg kg 1 of body weight for 14 days (Figure 6a). As shown in
Figure 6b, administration of rapamycin effectively halted the
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Figure 3. IFN-c deficiency increases Tregs and Teff to Treg ratio. (a) Splenocytes from age-matched h3TA2 or h3TA2-IFN-g / mice were stained with
fluorochrome-conjugated antibodies against hVb12, mCD4, mCD8, or mCD25 antibodies followed by forkhead box P3 (FoxP3) intracellular staining.
Representative data from one of three experiments are shown. (b) Bar diagram representing relative number of Treg (CD4þCD25þFoxP3þ ) cells. Data represent
mean±SD of three independent experiments. **Po0.01. (c) Bar representation of the Teff (Vb12þCD4CD8 ) versus Treg (CD4þCD25þFoxP3þ ) ratio for
h3TA2 or h3TA2-IFN-g / mice. Data represent mean±SD of three independent experiments. **Po0.01. (d) Splenocytes from h3TA2-IFN-g / (n¼3) mice
injected with anti-CD25 antibody were evaluated for Treg population by staining for CD4, CD25, and FoxP3. (e) h3TA2-IFN-g / mice injected intraperitoneally
(i.p.) weekly with anti-CD25 antibody (500mg per mouse) from 3 to 15 weeks of age and assessed for vitiligo development. (f) Splenocytes obtained from e were
TCR stimulated with cognate peptide (human tyrosinase peptide (h-Tyr)) and control peptide (MART-1). Supernatant was then evaluated for IL-17 and IL-22
secretion using ELISA. (g) Skin sections were prepared from e and stained for CD3 and IL-17a. Arrows: green, CD3; red, IL-17a; orange, merged CD3, IL-17a, and
4’,6-diamidino-2-phenylindole (DAPI). Bar¼ 94mm. CD3þ IL-17aþ T cells present per millimeter (mm)2 area of the skin sample were counted and are presented
graphically. (h) Supernatant obtained in f was evaluated using multiplex for different cytokines and chemokines as indicated. *Po0.05, **Po0.01, ***Po0.0001.
Teff, effector T cell; Treg, regulatory T cell.
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depigmentation process in h3TA2 mice compared with
untreated animals when measured 6 weeks after treatment.
Depigmentation was quantified at 6 weeks after treatment
as  3.3±0.78% in treated and 19.7±3.17% in untreated
animals subjected to rapamycin at 3 weeks of age. Pigmenta-
tion in rapamycin-treated areas was accompanied by retention
of melanocytes in the skin, as illustrated in Supplementary
Figure S2 online. Next, we examined whether rapamycin
treatment could increase the Treg population in h3TA2 mice.
Flow cytometric analysis suggests that rapamycin markedly
increased Treg cell abundance in h3TA2 mice (Figure 6c). We
then probed whether rapamycin treatment could also enhance
the suppressive potential of Tregs present in h3TA2 mice.
Tregs were sorted from both rapamycin-treated or -untreated
mice based on the surface expression of CD4þCD25hi
CD39hiCD73hi (480% of this population expressed FoxP3)
and cocultured in a 1:2 ratio with purified Vb12þ–transgenic
T cells in the presence of 1mg ml 1 h-Tyr antigen–pulsed irra-
diated surrogate antigen–presenting T2 cells. Our data show
that Tregs from both rapamycin-treated and untreated mice
are equally suppressive in the production of IFN-g by trans-
genic T cells upon stimulation by cognate antigen (Figure 6d).
Moreover, there were no marked differences in activation
phenotype of transgenic T cells as determined by the expres-
sion of CD44 and CD62L in either rapamycin-treated or
-untreated mice (Figure 6e). Thus, the observed differences
in depigmentation may be due to numeric differences in Treg
infiltration to the skin. Infiltration of Tregs was markedly
increased in the skin of treated animals as determined by
immunostaining (Figure 6f), and in situ reverse-transcriptase–
PCR (Bagasra (2007)) (Supplementary Figure S3 online), thus
establishing the importance of Tregs in controlling vitiligo
progression.
DISCUSSION
A number of studies strongly favor an autoimmune etiology for
vitiligo (Oyarbide-Valencia et al., 2006). Studies have shown
that skin biopsies from patients with vitiligo contain a greater
number of infiltrating cytotoxic T cells as compared with
healthy individuals (Le Poole et al., 1993, 1996). In this study,
we used our recently developed TCR transgenic mouse model
(h3TA2) of spontaneous vitiligo (Mehrotra et al., 2012) that
resembles the disease condition in humans and represents a
faithful model of aggressive disease not only to investigate the
potential immune mediators but also to test drugs that would
control autoimmunity.
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Therapeutic intervention of vitiligo requires mechanistic
insights into the factors contributing to depigmentation. It is
widely accepted that vitiligo results from the destruction of
functional melanocytes by skin-infiltrating cytotoxic T cells
(Steitz et al., 2004; Oyarbide-Valencia et al., 2006). Key
molecules responsible for cytotoxic effector function, such as
perforin, granzyme, TNF-a, and IFN-g have been implicated in
vitiligo progression in various models (van den Wijngaard
et al., 2000; Moretti et al., 2009; Gregg et al., 2010; Shi and
Erf, 2012). In the present study we found that neither perforin
nor TNF-a was essential for melanocyte destruction by
transgenic T cells. Another TCR transgenic model of sponta-
neous vitiligo found perforin deficiency dispensable for the
development of adult patterns of vitiligo (Gregg et al., 2010).
However, regulation of chemokine receptor expression on
T cells due to IFN-g deficiency was shown to impair
depigmentation (Gregg et al., 2010). Furthermore, in an
adoptive transfer model of epidermal depigmentation, it was
also shown that neutralization of IFN-g abrogates the
depigmentation process (Harris et al., 2012). In the present
study we describe that the increased ratio of Treg versus Teffs
is a critical factor in controlling the disease progression in IFN-
g-deficient mice. We found that IFN-g deficiency was
associated with a numerical increase in the FoxP3-positive
population in h3TA2 mice. Our results are consistent with
previous studies showing that IFN-g inhibits the generation
of Treg by a Signal Tansducers and Activators of Transcription-
1-mediated pathway (Caretto et al., 2010). The detailed
molecular pathways involving IFN-g in regulating Treg
development in a h3TA2 model warrants further investigation.
Autoreactive T cells are normally kept in check by Tregs.
Earlier studies from our group showed that the total number
of infiltrating Tregs was drastically reduced in vitiligo skin
(Klarquist et al., 2010). In accordance with the previous study,
herein we also highlight a decisive role of Tregs in regulating
vitiligo pathogenesis using h3TA2 mice. Interestingly, when
Tregs were depleted in h3TA2-IFN-g / mice, an array of
proinflammatory cytokines were secreted by transgenic T cells
upon TCR antigen-specific restimulation. This included IL-2,
IL-3, IL-4, IL-5, IL-6, GM-CSF, and MIP-2—several of which
were shown to be upregulated in vitiligo patient serum
(Tu et al., 2003; Singh et al., 2012). The role for these
proinflammatory cytokines and chemokines has also been
correlated with clinical phenotypes in uveitis patients
(Ooi et al., 2006). In addition, the levels of IL-17 and IL-22
secretion were increased after Treg depletion. Both IL-17 and
IL-22 have been recently implicated in the pathogenesis of
human vitiligo and psoriasis (Ratsep et al., 2008; Kagami
et al., 2010; Bassiouny and Shaker, 2011; Wang et al., 2011;
Elela et al., 2013). Our data highlight that a switch to the
multiple cytokine–secreting ability of T cells was regulated by
Treg in h3TA2 mice and the disruption of the delicate balance
between Teffs and Treg could result in a cytokine storm
leading to the development of vitiligo.
We further demonstrate that, although the reduced Teff to
Treg ratio essentially governs the development of vitiligo in
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h3TA2 mice, a quantitative increase in Tregs by adoptive
transfer controlled vitiligo progression. This indicates that a
critical ratio of Teffs to Treg must be maintained/achieved in
order to prevent the development of vitiligo in h3TA2 mice.
The main prerequisite for Treg therapy is maintenance of
FoxP3þ cells at the site of inflammation. However, limited
availability of Tregs owing to limitations in amplification from
an autologous source is a major constraint for their clinical
application (Nadig et al., 2010; Bailey-Bucktrout and
Bluestone, 2011; Safinia et al., 2013). Keeping this in mind,
herein we also evaluated whether vitiligo could be controlled
by the pharmacological inhibitor of mammalian target of
rapamycin, rapamycin that has the potential to sustain and
expand the Tregs in vivo (Putnam et al., 2009; Scotta et al.,
2013). Our study shows that rapamycin treatment can
efficiently halt the depigmentation process by increasing the
abundance of Treg in h3TA2 mice. This is consistent with
previous studies showing that rapamycin treatment increased
the naive T cell to Treg conversion rate in vivo (Daniel et al.,
2010) and that it ameliorates the function of the resulting Tregs
(Scotta et al., 2013). We observed that the protective effect
of rapamycin was maintained in vitiligo-prone mice even
6 weeks after completion of treatment. This can be explained
by the fact that rapamycin is crucial to conferring stability
upon expanded Tregs even under inflammatory conditions.
Although we noticed a quantitative increase in Tregs from
rapamycin-treated h3TA2 mice, any qualitative difference on
a per cell basis was not noticed. This implies that with
increased Tregs and with a reduced Teff to Treg ratio, the
inhibition of effector function by increased infiltration of Tregs
to the skin could have had a role in controlling vitiligo. In
addition to expanding Tregs, rapamycin has also been shown
to control transcription of melanogenic enzymes and
melanosomal maturation (Ho et al., 2011; Wataya-Kaneda
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et al., 2012), and thus a potential synergy leading to vitiligo
control may exist.
In summary, in the present study we demonstrate that
modulation of Teff to Treg ratios can be beneficial in the
treatment of vitiligo. Our data support a potential for adoptive
Treg transfer or rapamycin as a therapeutic modality for the
treatment of vitiligo, and its use in future clinical trials.
MATERIALS AND METHODS
Mice
The development of h3TA2 transgenic mice bearing TCR reactive to
the h-Tyr 368-376 (YMDTMSQV) epitope has been described recently
(Mehrotra et al., 2012). To generate the h3TA2 with knockout genes,
breeding was established with CXCR3 / (stock number 005796),
CCR5 / (stock number 005427), TNF-a / (stock number 003008),
IFN-g / (stock number 002287), and perforin / (stock number
002407) from Jackson Laboratory (Bar Harbor, ME). Animals were
maintained in pathogen-free facilities and under the approved
procedures of the Institutional Animal Care and Use Committee.
Quantification of depigmentation
Degree of depigmentation in mouse strains was measured using a
flatbed scanner (EPSON, Long Beach, CA) and Adobe Software
(Adobe Systems, San Jose, CA). The percentage of depigmentation
was calculated as described earlier (Denman et al., 2008).
Reagents
h-Tyr (YMDGTMSQV), and murine tyrosinase peptide
(FMDGTMSQV) were purchased from Genzyme (Cambridge, MA).
Culture medium used was Iscove’s modified Dulbecco’s media (Life
Technologies, Grand Island, NY) supplemented with 10% fetal
bovine serum (BioAbChem, Ladson, SC). Fluorochrome-conjugated
antibodies for CD3 (clone 145-2C11), CD4 (clone GK1.5), CD8 (53-
6.7), CD25 (clone 3C7), CD44 (clone IM7), and CD62L (MEL-14)
were purchased from BioLegend (San Diego, CA), and for human
Vb12 were purchased from Thermo Scientific (Rockford, IL).
Flow cytometry
Staining for cell surface markers was performed by incubating
cells with antibody at 1:200 dilutions in FACS buffer (0.1%
BSA in phosphate-buffered saline) for 30 minutes at 4 1C. For intracel-
lular staining, surface markers were stained before fixation/
permeablization of cells for intracellular staining of IFN-g
(XMG1.2), IL-17a (TC11-18H10.1), IL-10 (JES5-16E3), TNF-a
(MP6-XT22), or FoxP3 (FJK-16s; FoxP3 staining buffer set from
eBioscience, San Diego, CA). Samples were acquired on LSR Fortessa
and analyzed with FlowJo software (Tree Star, Ashland, OR). MoFlo
Astrios (Beckman Coulter, Fullerton, CA) cell sorter was used to
obtain 99% Vb12þCD3þ cells from h3TA2 splenocytes. To purify
Tregs from splenocytes of h3TA2 or h3TA2 mice treated with
rapamycin, FACS sorting was performed for cells with CD4þ
CD25hiCD39hiCD73hi phenotype.
Depletion of Treg in vivo
Depletion of Treg in h3TA2-IFN-g / mice was achieved by
injecting anti-CD25 mAb. In brief, h3TA2-IFN-g / mice were
injected intraperitoneally with 500mg per mouse anti-CD25 antibody
(clone PC61) weekly for 12 weeks beginning at 3 weeks of age.
Adoptive transfer of Treg in h3TA2 mice
FoxP3-EGFP-A2 mice were developed by breeding FoxP3-EGFP mice
(Jackson Laboratory, stock number 006769) with HLA-A2 mice
(Jackson Laboratory; stock number 003475). CD4þCD25þGFP
(FoxP3)þ cells were then sorted using MoFlo Astrios (Beckman
Coulter). Purified (498%) Tregs (200,000 per animal) were trans-
ferred intravenously into h3TA2 mice along with recombinant IL-2 at
9,000 IU per animal intraperitoneally for 10 days in order to maintain
the Treg population.
Immunostaining
Skin samples were isolated from mice, embedded in Optimal Cutting
Temperature compound (Electron Microscopy Sciences, Hatfield,
PA), snap frozen, and then sectioned into 8-mm sections onto
SuperFrost Plus slides (Electron Microscopy Sciences). Sections for
detecting FoxP3 or tyrosinase related protein-1 were then fixed in
cold acetone or paraformaldehyde for IL-17a detection. For immuno-
fluorescent staining, tissue sections were blocked using SuperBlock
(ScyTek Labs, West Logan, UT) before staining with FITC-conjugated
CD3 (BD Biosciences, 145-2C11) and phycoerythrin-conjugated FoxP3
(BioLegend, MF-14). For IL-17a staining, unlabeled IL-17a (BD
Biosciences, San Jose, CA, TC11-18H10) followed by biotin-conju-
gated mouse anti-rat (eBioscience) and, finally, phycoerythrin-conju-
gated streptavidin (South Biotech, Birmingham, AL) were used. Slides
were counterstained with 4’,6-diamidino-2-phenylindole. Micrographs
were taken on an Olympus (Center Valley, PA) AX80T Microscope and
merged in Adobe Photoshop version 13.0 (San Jose, CA).
Rapamycin treatment of h3TA2 mice
Rapamycin at 5mgkg 1 of body weight in vivo dose was used to treat
h3TA2 mice according to the published protocol (Daniel et al., 2010).
Treg-mediated suppression of IFN-c production by transgenic
T cells and ELISA
To determine Treg-mediated suppression of IFN-g production by
transgenic T cells, CD3þVb12þ T cells (2 105 cells) were com-
bined in a 1:10 ratio with antigen–pulsed (h-Tyr, 1mg ml 1)–
irradiated (3,000 rad) T2 cells and cocultured overnight with
Tregs purified from either h3TA2 mice or h3TA2 mice treated with
rapamycin at 2:1 ratio (transgenic T cells: Tregs). Culture supernatants
generated with or without Tregs were used to measure cytokines
using ELISA according to the manufacturer’s protocol (R&D Systems,
Minneapolis, MN) or using mouse cytokine/chemokine 32-plex array
panel (Eve Technologies, Calgary, AB, Canada).
Statistical analysis
All data reported are the arithmetic mean from three or five
independent experiments performed in triplicate±SD unless stated
otherwise. The unpaired Student’s t-test was used to evaluate the
significance of differences observed between groups, accepting
Po0.05 as a threshold of significance. Data analyses were performed
using the Prism software (GraphPad, San Diego, CA).
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